← Human Trials & Peer-Reviewed Studies
Vasoactive intestinal Peptide as a diagnostic or prognostic biomarker in multiple sclerosis: A systematic review.
Plain-language guide to PMID 42447728 (2026): systematic review of VIP (Vasoactive Intestinal Peptide), multiple sclerosis.
Key Facts
- PMID
- 42447728
- Journal
- Multiple sclerosis and related disorders
- Year
- 2026
- Study type
- Systematic Review
- Authors
- Cabrera-Martín A et al. (4 authors)
- DOI
- 10.1016/j.msard.2026.107377
What This Paper Covers, in Plain Language
What It Covers
Researchers studied VIP (Vasoactive Intestinal Peptide) in the context of multiple sclerosis in this systematic review publication.
Vasoactive intestinal peptide (VIP) is an immunomodulatory and neuroprotective neuropeptide with established effects in preclinical models, but its biomarker utility remains uncertain.
This review evaluated VIP expression as an MS biomarker.
Who the Included Studies Covered
Eligible studies included original clinical research measuring VIP levels, genetic variants, or expression of VIP and its receptors in MS patients.
How the Review Was Done
A systematic search of PubMed, Embase, and Cochrane databases was conducted according to PRISMA guidelines.
Reviews, non-clinical, animal or in vitro studies, and non-English publications were excluded.
Study selection and data extraction were performed independently by several reviewers.
Due to methodological heterogeneity, qualitative synthesis was conducted, and risk of bias was assessed using the QUADAS-2 tool.
What Was Measured
Vasoactive intestinal peptide (VIP) is an immunomodulatory and neuroprotective neuropeptide with established effects in preclinical models, but its biomarker utility remains uncertain.
This review evaluated VIP expression as an MS biomarker.
Topics PubMed links to this paper include Biomarkers, Multiple Sclerosis, Prognosis and Vasoactive Intestinal Peptide.
Author keywords: Diagnostic and Prognostic.
What This Means in Plain Language
This is a systematic review of VIP (Vasoactive Intestinal Peptide) in people with multiple sclerosis.
The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2026 (Multiple sclerosis and related disorders), a journal based in Netherlands.
More context: the VIP (Vasoactive Intestinal Peptide) compound page, Multiple sclerosis research.
Our Notes on the Compound
VIP (Vasoactive Intestinal Peptide): A 28-amino-acid neuropeptide that relaxes smooth muscle and calms immune activity; aviptadil is a synthetic form.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.